Scarica l'app Stockscreener
8.67
7.17%
-0.67
Dopo l'orario di chiusura:
8.62
-0.05
-0.58%
Precedente Chiudi:
$9.34
Aprire:
$9.37
Volume 24 ore:
1.04M
Relative Volume:
0.76
Capitalizzazione di mercato:
$525.32M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-0.6674
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
-7.77%
1M Prestazione:
+7.97%
6M Prestazione:
-3.02%
1 anno Prestazione:
-8.16%
Intervallo 1D:
$8.64
$9.37
Intervallo di 1 settimana:
$8.64
$10.08
Portata 52W:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.67 | 565.91M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Price-Driven Insight from (DNA) for Rule-Based Strategy - news.stocktradersdaily.com
What analysts say about Ginkgo Bioworks Holdings Inc stockDividend Stability Analysis & Rapid Portfolio Gain - earlytimes.in
Is Ginkgo Bioworks Holdings Inc a good long term investmentSector-Based Investing & Rapid Capital Appreciation - earlytimes.in
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - Investing News Network
Jump Financial LLC Acquires New Stake in Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Recent Uptick Might Appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Institutional Owners After Losing 13% Over the Past Year - 富途牛牛
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform - marketscreener.com
Ginkgo Bioworks Partners on Deep Origin-Led Team to Develop New Tools for Pred Predictive Drug Safety - marketscreener.com
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - Finviz
Ginkgo Bioworks partners with Deep Origin on ARPA-H drug safety project - Investing.com UK
Ginkgo Bioworks (NYSE: DNA) to aid ARPA-H CATALYST drug safety modeling platform - Stock Titan
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpWhat's Next? - MarketBeat
Ginkgo Bioworks to Hold Special Meeting of Shareholders - GuruFocus
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform - Investing.com
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform By Investing.com - Investing.com South Africa
Ginkgo Bioworks Awarded 4-Year Energy Department Contract Valued at Up to $47 Million - marketscreener.com
Ginkgo Bioworks stock rises on $47M DOE contract award By Investing.com - Investing.com South Africa
Ginkgo Bioworks stock rises on $47M DOE contract award - Investing.com India
Ginkgo Bioworks Holdings Inc selected by PNNL to deliver a modular, high-throughput phenotyping platform for DOE's M2PC - marketscreener.com
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High-Throughput Phenotyping Platform for DOE's M2PC - Finviz
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC - marketscreener.com
Will Ginkgo Bioworks Holdings Inc. Class stock announce a stock splitCEO Change & AI Based Buy and Sell Signals - Newser
Is Ginkgo Bioworks Holdings Inc. stock a buy before product launchesMarket Rally & Consistent Growth Equity Picks - Newser
Ginkgo Bioworks Holdings, Inc. $DNA Holdings Boosted by Geode Capital Management LLC - MarketBeat
Ginkgo Bioworks Collaborates With Strm.Bio, Partners on ARPA-H Contract for Cell Engineering, Gene Therapy - marketscreener.com
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy - Finviz
Ginkgo Bioworks (NYSE: DNA) partner STRM.BIO lands ARPA-H deal worth up to $8.4M - Stock Titan
Ginkgo Bioworks Holdings (DNA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ginkgo Bioworks Holdings, Inc. $DNA Position Lifted by Legal & General Group Plc - MarketBeat
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions (PR Newswire) - Aktiellt
Retail Trends: Is Ginkgo Bioworks Holdings Inc. stock a contrarian buyJuly 2025 Drop Watch & Risk Managed Investment Signals - BỘ NỘI VỤ
Will Ginkgo Bioworks Holdings Inc. stock recover faster than marketJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - BỘ NỘI VỤ
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors (PR Newswire) - Aktiellt
(DNA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Ginkgo Bioworks Holdings Inc. Class stock compares with tech leaders2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - newser.com
How Ginkgo Bioworks Holdings Inc. Class stock benefits from digital adoptionStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ginkgo Bioworks (DNA) Leverage ARPA-H Partnership to Advance Its Oral Therapeutics Ambitions? - Yahoo Finance
Ginkgo Bioworks: Scaling Science, Not Revenue (NYSE:DNA) - Seeking Alpha
Is Ginkgo Bioworks Holdings Inc. Class stock resilient in recession scenarios - newser.com
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Ginkgo Bioworks Holdings Inc. stock daily chart insightsJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can Ginkgo Bioworks Holdings Inc. stock beat market expectations this quarter - newser.com
Will Ginkgo Bioworks Holdings Inc. stock gain from lower inflationWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Is it time to cut losses on Ginkgo Bioworks Holdings Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
Exit strategy if you’re trapped in Ginkgo Bioworks Holdings Inc.2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
Can Ginkgo Bioworks Holdings Inc. stock surprise with earnings upsideEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):